Trials / Not Yet Recruiting
Not Yet RecruitingNCT06424977
Biomarker Targeted Stimulation for Epileptiform Events
Safety and Effectiveness of Biomarker Targeted Stimulation in Epilepsy
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Cadence Neuroscience · Industry
- Sex
- Male
- Age
- 7 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, prospective, controlled study designed to evaluate treatment with the BTS System.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Biomarker Targeted Stimulation (BTS) | Using continuous stimulation to target multiple network nodes, Biomarker Targeted Stimulation (BTS) is intended to suppress abnormal interictal activity, as determined by biomarkers including interictal epileptiform discharges (IED) and high frequency oscillations (HFO), with the intention to reduce brain hyperexcitability, thereby limiting seizure occurrence. |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2027-12-01
- Completion
- 2029-09-01
- First posted
- 2024-05-22
- Last updated
- 2025-02-21
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06424977. Inclusion in this directory is not an endorsement.